If gastrointestinal symptoms significantly impair quality of life or prevent medication adherence despite conservative management, healthcare providers may consider dose adjustment, alternative agents with potentially different side effect profiles, or referral to a gastroenterologist for specialized evaluation
Reddy's on April 28, 2026 [9] and Apotex on May 1, 2026 [10]) after the data exclusivity period expired on January 4, 2026
Recent findings have indicated that levels of the atypical methyltransferase METTL1 are elevated in cancer cells, thereby promoting glutamine synthase (GLUL) expression in an m6A-dependent manner, which in turn facilitates cancer cell proliferation [44]
Recent surveys show more employers are starting to cover GLP-1s for obesity, even as the drugs are driving up health costs
The 28.7% average weight loss observed in TRIUMPH 4 places this medication in a category of its own, which should strengthen the case for expedited review
Retatrutide-associated studies may examine lipolysis, lipid storage, adipocyte differentiation, insulin signaling, mitochondrial activity and transcriptional responses
